Roche Holding AG, the Basel, Switzerland-based drugmaker that manufactures the world’s best- selling cancer treatment and reached a five-year high this week, has minted at least 12 Swiss and German billionaires. Seven have never appeared individually on an international wealth ranking.
Novartis AG’s Gilenya multiple sclerosis pill lost market share for the first time in January, following the deaths of some patients soon after taking the first pill available for the disease in the U.S.
Illumina Inc. gained the most in almost a year after Swiss newspaper L’Agefi said Roche Holding AG may have agreed to buy the U.S. maker of DNA sequencing equipment at a price 48 percent higher than its original unsuccessful bid.
Novartis AG backed off a prediction that a U.S. factory will resume making products such as the athlete’s foot gel Lamisil this year after shutting the facility in January because of manufacturing flaws.